Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
ID: 353830Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353830

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-004.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) aimed at supporting clinical trials focused on the prevention of type 1 diabetes (T1D) and the preservation of insulin production. This cooperative agreement, identified as RFA-DK-25-004, seeks to continue the existing project by facilitating a wide range of research activities, including data management and the selection of Clinical Centers, while emphasizing the importance of a Plan for Enhancing Diverse Perspectives (PEDP) to foster inclusivity in research. The funding amount is projected to reach approximately $29.5 million per year, with a maximum project duration of five years, and key deadlines include a letter of intent and full application submissions due by September 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-004.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-004-Full-Announcement.html
    RFA-DK-25-004.html
    The National Institutes of Health (NIH) is offering funding through the Coordinating Center for Type 1 Diabetes TrialNet (TNCC) to support clinical trials aimed at preventing type 1 diabetes (T1D) and preserving insulin production. The funding opportunity, numbered RFA-DK-25-004, is a continuation of the existing project and emphasizes collaboration and scientific leadership for ongoing and new intervention studies. The TNCC will handle data management, selection of Clinical Centers, and network administration, with a strong requirement for a Plan for Enhancing Diverse Perspectives (PEDP) to enhance inclusivity in research. Key dates for application submissions include a letter of intent due on September 16, 2024, and full applications also due by the same date. The funding amount intends to reach approximately $29.5 million per year, with a maximum duration of five years for the awarded projects. Eligible applicants include higher education institutions and various nonprofit and government entities situated in North America, with an emphasis on those integrating diverse perspectives. The document enforces strict guidelines regarding application procedures and encourages proactive communication to facilitate efficient trial operations, reflecting a strategic effort to advance T1D prevention and treatment research.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDDK Education Program Grants (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering Research Education Program Grants (R25) to enhance training in biomedical, behavioral, and clinical research. This funding opportunity aims to support educational activities that develop research skills and provide hands-on experiences in areas critical to NIDDK, including diabetes, digestive diseases, and obesity. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and local governments, with a funding limit of $100,000 per year for up to five years. The application deadline is January 30, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-074.html.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small Research Project Grants (R01s) aimed at clinical trials focused on diseases under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative encourages the submission of pilot and feasibility clinical trials that will provide foundational data for larger, definitive trials intended to improve the prevention and treatment of various health conditions, without the requirement of preliminary efficacy data. The program supports innovative research ideas and emphasizes equitable recruitment from diverse populations, with a maximum grant duration of three years and funding up to $200,000 per year. Interested applicants can find more information and submit their applications by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Impact, Interdisciplinary Science in NIDDK Research Areas" (PAR-25-277) aimed at supporting innovative research that addresses critical knowledge gaps in diabetes, digestive, and kidney diseases. This grant program encourages interdisciplinary approaches to foster discovery-based science and develop transformative technologies that can significantly impact the broader scientific community. Eligible applicants include a wide range of organizations, such as higher education institutions and nonprofits, with proposals accepted for projects lasting up to five years. Interested parties should ensure compliance with application guidelines and submit their proposals by the deadline of October 15, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-277.html.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)." This initiative aims to promote exploratory research into the biological mechanisms by which incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk, with a focus on understanding their effects beyond diabetes treatment. The funding, which amounts to a maximum of $275,000 over two years, is intended to attract diverse researchers and institutions to fill significant gaps in current cancer biology research. Interested applicants should note that the application submission period begins on January 16, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.
    NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) to support pioneering biomedical research focused on critical scientific challenges related to diabetes, digestive diseases, and kidney diseases. This grant aims to fund individual scientists proposing innovative and high-impact studies that diverge from their existing research, encouraging bold ideas and unconventional hypotheses within the domains of the Division of Diabetes, Endocrinology and Metabolic Diseases and the Division of Digestive Diseases and Nutrition. The award has a budget ceiling of $500,000 per year for a maximum project period of five years, with a total funding commitment of $4.8 million for FY 2026 to support up to six awards. Interested applicants must adhere to NIH registration requirements and submit their proposals by July 18, 2025, with further inquiries directed to grantsinfo@nih.gov.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.